3.Chemotherapy of Acute Lymphoblastic Leukemia in Children.
Korean Journal of Pediatric Hematology-Oncology 2003;10(2):155-161
No abstract available.
Child*
;
Drug Therapy*
;
Humans
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma*
8.A case of aseptic meningitis following intrathecal administration of methotrexate.
Jin Kuk DO ; Kyu Ho KWAK ; Hee Jong OH ; Dong Kuck LEE
Journal of the Korean Neurological Association 1997;15(1):233-236
Methotrexate(MTX) is currently one of the most important antineoplastic drugs used in chemotherapy. Intrathecal(IT) MTX is widely used to treat or prevent meningeal leukemia and lymphoma. Aseptic meningitis following IT MTX is not uncommon, but not reported frequently in neurological field. We report a case of aseptic meningitis following IT MTX in acute lymphocytic leukemia.
Antineoplastic Agents
;
Drug Therapy
;
Leukemia
;
Lymphoma
;
Meningitis, Aseptic*
;
Methotrexate*
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9.Efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation treatment for T lymphoblastic leukemia/lymphoma.
Lan LUO ; Yang JIAO ; Ping YANG ; Yan LI ; Wen Yang HUANG ; Xiao Yan KE ; De Hui ZOU ; Hong Mei JING
Chinese Journal of Hematology 2023;44(5):388-394
Objective: To analyze the efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for treating T lymphoblastic leukemia/lymphoma (T-ALL/LBL) . Methods: This study retrospectively evaluated 119 adolescent and adult patients with T-ALL/LBL from January 2006 to January 2020 at Peking University Third Hospital and Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences. Patients were divided into chemotherapy-only, chemotherapy followed by allo-HSCT, and chemotherapy followed by autologous hematopoietic stem cell transplantation (auto-HSCT) groups according to the consolidation regimen, and the 5-year overall survival (OS) and progression-free survival (PFS) rates of each group were compared. Results: Among 113 patients with effective follow-up, 96 (84.9%) patients achieved overall response (ORR), with 79 (69.9%) having complete response (CR) and 17 (15.0%) having partial response (PR), until July 2022. The analysis of the 96 ORR population revealed that patients without transplantation demonstrated poorer outcomes compared with the allo-HSCT group (5-year OS: 11.4% vs 55.6%, P=0.001; 5-year PFS: 8.9% vs 54.2%, P<0.001). No difference was found in 5-year OS and 5-year PFS between the allo-HSCT and auto-HSCT groups (P=0.271, P=0.197). The same results were achieved in the CR population. Allo-HSCT got better 5-year OS (37.5% vs 0) for the 17 PR cases (P=0.064). Different donor sources did not affect 5-year OS, with sibling of 61.1% vs hap-haploidentical of 63.6% vs unrelated donor of 50.0% (P>0.05). No significant difference was found in the treatment response in the early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP) and non-ETP populations. The ETP group demonstrated lower 5-year OS compared with the non-ETP group in the chemotherapy alone group (0 vs 12.6%, P=0.045), whereas no significant difference was found between the ETP and non-ETP groups in the allo-HSCT group (75.0% vs 62.9%, P=0.852). Multivariate analysis revealed that high serum lactate dehydrogenase level, without transplantation, and no CR after chemotherapy induction were independently associated with inferior outcomes (P<0.05) . Conclusion: Allo-HSCT could be an effective consolidation therapy for adult and adolescent patients with T-ALL/LBL. Different donor sources did not affect survival. Allo-HSCT may overcome the adverse influence of ETP-ALL/LBL on OS.
Adult
;
Adolescent
;
Humans
;
Prognosis
;
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
;
Retrospective Studies
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy*
;
Hematopoietic Stem Cell Transplantation
;
Lymphoma, T-Cell
;
Unrelated Donors
Result Analysis
Print
Save
E-mail